Compare The Coca-Cola Co K (KO) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Coca-Cola Co K vs GeneDx Holdings Corp — how do they compare? The Coca-Cola Co K trades at $81.87 (market cap $353.32B), while GeneDx Holdings Corp trades at $60.5 (market cap $1.80B). The key difference: The Coca-Cola Co K is far larger — about 196.3× GeneDx Holdings Corp's market cap, and The Coca-Cola Co K pays a 2.58% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| KO | WGS | |
|---|---|---|
Market Cap | $353.32B | $1.80B |
Volume | 14,630,257 | — |
Sector | Consumer Staples | Technology |
52-Week High | $84.92 | $167.51 |
52-Week Low | $65.67 | $34.51 |
Enterprise Value | $383.39B | $1.80B |
Dividend Yield | 2.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $81.56, down 3.96% on the day, with a bearish technical signal but strong fundamentals including a 27.8% net income margin and consistent earnings beats. Recent news highlights institutional accumulation and steady dividend payments. The stock is supported by robust cash flow and brand strength, though near-term price action shows weakness below key resistance.
Outlook remains positive with a consensus price target of $90.67, offering ~11% upside. Risks include regional demand divergence and high debt levels. The stock presents a value opportunity for dividend-focused investors given its 64-year dividend growth streak, but macroeconomic pressures warrant caution.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% amid a bearish technical signal and negative profitability. Recent earnings showed a Q1 2026 miss after two prior beats, with revenue growth but widening losses projected for 2026. The stock faces significant headwinds from multiple securities class action lawsuits alleging misrepresentations, with a deadline of August 3, 2026.
Despite a high analyst buy consensus (90.9%) and a $75.40 price target implying 24% upside, risks are elevated due to litigation, negative margins, and a high EV/EBITDA of 161.17. The upcoming Q2 2026 results on August 3 will be critical for investor confidence, but the legal overhang and fundamental challenges suggest cautious near-term outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
